Exicure, Inc. (XCUR)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.15
- As of
Kresmion compiles this page from XCUR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
EXICURE, INC. (XCUR): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
See the full XCUR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XCUR on one page. Preview it with sample data, then open it live with a free account.
Preview the XCUR dossierActive signals for XCUR
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in XCUR
- mediumEARNINGS_MISS
Q3-2021: Missed consensus by 178.6% - EPS $-40.5 vs $-14.535 estimate
- mediumEARNINGS_MISS
Q4-2021: Missed consensus by 5.0% - EPS $-22.5 vs $-21.42 estimate
- mediumEARNINGS_MISS
Q2-2022: Missed consensus by 35.6% - EPS $-8.3 vs $-6.12 estimate
- mediumEARNINGS_MISS
Missed consensus by 178.6% - EPS $-40.5 vs $-14.535 estimate
FREE, NO ACCOUNT
Every signal on XCUR, as it fires
You are seeing 5 of 7 signals recorded on XCUR since 2026-05-26.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XCUR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 30205M309 · 2026Q2 | $31K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XCUR
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
XCUR against its peers
XCUR's return on equity of -126.0% ranks in the 66th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | XCUR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 1.2M USD | 11 | 13 |
| Revenue YoY | n/a | -21.8% | n/a | 5 |
| Gross margin | n/a | 63.4% | n/a | 7 |
| Operating margin | n/a | -484.3% | n/a | 11 |
| Net margin | n/a | -484.6% | n/a | 11 |
| Return on equity | -126.0% | -197.1% | 66 | 18 |
| 1 year | -77.6% | -81.4% | 57 | 14 |
Peers (21): APRE, BOLT, IMNN, KPTI, ACXP, AIM, KALA, RVPH, CELZ, CSCIF, ALZN, CANF, SKYE, AAGH, CLGN, EVGN, CURX, CNSP, AZTR, LGVN, OSRH. Left out: ADAPY (no annual filing), ENVB (no annual filing), LIANY (no annual filing), NRSN (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (XCUR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XCUR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XCUR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.